HC Wainwright & Co. Reiterates Buy on Cartesian Therapeutics, Maintains $25 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $25 price target.
Last updated: 2026-11-19 20:06:00. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Cartesian Therapeutics, Inc. (RNAC) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $5.89, with a market capitalization of $186.68M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $5.60 to $11.00. This page covers its latest market performance, valuation, price trends and company information.
$186.68M | |
$6.33 | |
$6.35 | |
$5.82 | |
$6.30 | |
167.89K | |
133.99K | |
-- | |
$11.00 | |
$5.60 | |
-- | |
2026-09-30 |
Cartesian Therapeutics, Inc. (RNAC) is currently trading at $5.89 as of 2026-11-19 20:05:00, down 6.27% ($0.39) from the previous close of $6.30
During today's regular trading session, RNAC has traded between $5.82 and $6.35, with a trading volume of 167.89K shares. The current price is near the lower end of today's range.
Over the past seven days, Cartesian Therapeutics, Inc. (RNAC) moved from $6.89 to $5.89, representing a decline of 14.59% ($1.01).
The stock traded between $5.82 and $7.28 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 157.44 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 5.3%
RNAC is currently trading at $5.89, placing it 5.3% of the way from its 52-week low of $5.60 to its 52-week high of $11.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering cell therapy for the treatment of autoimmune diseases. The company uses technology and a manufacturing platform to introduce mRNA into cells to provide a therapeutic effect to patients suffering from a variety of autoimmune conditions. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 75 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Cartesian Therapeutics, Inc. and RNAC stock.
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $25 price target.
DelveInsight released a comprehensive competitive landscape report on BCMA-targeted therapies, analyzing 100+ pipeline drugs across 80+ companies. The report highlights recent clinical advances including Pfizer's positive Phase III results for ELREXFIO, AbbVie's BLA submission for etentamig, and Gilead's $7.8 billion acquisition of Arcellx to gain control of anito-cel. Key challenges include treatment resistance, relapse, and manufacturing complexity, while the pipeline focuses on improving durability, safety, and accessibility through next-generation approaches.
Eligible investors can buy real shares of Cartesian Therapeutics, Inc. (RNAC) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to RNAC, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between RNAC shares and USD.
RNAC Shares to USD
1.00 RNAC shares = 5.885 USD
Calculations are estimates based on the latest available price and are for reference only.